EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liver‐Specific Suppression of PLA2G6 / iPLA 2 β Improves Glucose and Lipid Metabolism in High‐Fat Diet‐Fed Mice

Kahori Shimizu iD, Mana Nishibata, Katsuyuki Nagata, Sho Hori, Shotaro Michinaga, Miyuki Kanehara, Miho Hashimoto-Iwasaki, Fuminori Sakurai, Hideo Shindou iD, Koji Tomita, Toru Nishinaka, Hiroyuki Mizuguchi iD

The FASEB Journal · 30.04.2026 · 40 (8)

DOI: 10.1096/fj.202504753rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 20.04.2026. Verfasst von Kahori Shimizu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Lipid Metabolism, Liver, Diet, High-Fat, Group VI Phospholipases A2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Mishima Kaiun Memorial Foundation, BOMU MELLNESS FOUNDATION.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phospholipase A2 group VI (PLA2G6, also called iPLA 2 β) has been implicated in male fertility, neuronal disorders, and metabolic diseases. However, its therapeutic effects on metabolic disorders remain elusive. We investigated the effects of PLA2G6 suppression on glucose and lipid metabolism. Systemic inhibition of PLA2G6 in high‐fat diet‐fed mice reduced hepatic lipid droplet size without altering the levels of serum triglycerides and fasting blood glucose. Suppression of liver‐specific Pla2g6 utilizing the short‐hairpin RNA knockdown technique using an adenovirus vector (Ad‐shPLA2G6) altered phospholipid and fatty acid metabolites and suppressed hepatic lipid accumulation, serum triglyceride, fasting glucose, and insulin levels. Additionally, Ad‐shPLA2G6 treatment downregulated lipid biosynthesis‐related genes but upregulated peroxisomal fatty acid oxidation‐related genes. These findings indicate that targeting hepatic Pla2g6 modulates phospholipid and fatty acid metabolites and improves glucose and lipid metabolism, suggesting Pla2g6 as a potential therapeutic target in metabolic disorders, including type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipid MetabolismLiverDiet, High-FatGroup VI Phospholipases A2GlucoseAnimalsMiceMaleMice, Inbred C57BLPhospholipidsTriglyceridesInsulinBlood GlucoseRNA, Small Interfering

Stichwörter der Autor:innen

PLA2G6adenovirus vectordiabetes mellitusmetabolic disordersmetabolic dysfunction‐associated steatotic liver diseasephospholipids

Substanzen

Group VI Phospholipases A2Pla2g6 protein, mouseGlucosePhospholipidsTriglyceridesInsulinBlood GlucoseRNA, Small Interfering

Autor:innen und Institutionen

  • Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.
  • Laboratory of Biochemistry and Molecular Biology, School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan.
  • Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
  • Department of Molecular Biology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Pharmacodynamics, Meiji Pharmaceutical University, Tokyo, Japan.
  • Laboratory of Biopharmaceutics, Faculty of Pharmacy, Kindai University, Osaka, Japan.

ORCID-Profile: Kahori Shimizu, Hideo Shindou, Hiroyuki Mizuguchi

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Mishima Kaiun Memorial Foundation
  • BOMU MELLNESS FOUNDATION
  • Takara Bio Research Award
  • Osaka Ohtani University Research Foundation
  • Japan Agency for Medical Research and Development (AMED)
  • NCGM Intramural Research Fund
  • Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) fro…

Zitieren

APA

Shimizu, K., Nishibata, M., Nagata, K., Hori, S., Michinaga, S., Kanehara, M., Hashimoto-Iwasaki, M., Sakurai, F., Shindou, H., Tomita, K., Nishinaka, T., & Mizuguchi, H. (2026). Liver‐Specific Suppression of PLA2G6 / iPLA 2 β Improves Glucose and Lipid Metabolism in High‐Fat Diet‐Fed Mice. The FASEB Journal, 40(8). https://doi.org/10.1096/fj.202504753rr

Vancouver

Shimizu K, Nishibata M, Nagata K, Hori S, Michinaga S, Kanehara M, et al. Liver‐Specific Suppression of PLA2G6 / iPLA 2 β Improves Glucose and Lipid Metabolism in High‐Fat Diet‐Fed Mice. The FASEB Journal. 2026;40(8). doi:10.1096/fj.202504753rr

BibTeX
@article{Shimizu2026,
  author = {Shimizu, Kahori and Nishibata, Mana and Nagata, Katsuyuki and Hori, Sho and Michinaga, Shotaro and Kanehara, Miyuki and Hashimoto-Iwasaki, Miho and Sakurai, Fuminori and Shindou, Hideo and Tomita, Koji and Nishinaka, Toru and Mizuguchi, Hiroyuki},
  title = {Liver‐Specific Suppression of PLA2G6 / iPLA 2 β Improves Glucose and Lipid Metabolism in High‐Fat Diet‐Fed Mice},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {8},
  doi = {10.1096/fj.202504753rr}
}
Kostenlos starten →